(Q35684830)

9 August 2017

1 reference

title

Safety and side effects of the acne drug, oral isotretinoin (English)

1 reference

9 August 2017

Charakida A

1

1 reference

9 August 2017

Mouser PE

series ordinal

2

1 reference

9 August 2017

Chu AC

series ordinal

3

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 March 2004

1 reference

Expert Opinion on Drug Safety

9 August 2017

1 reference

9 August 2017

3

1 reference

9 August 2017

2

1 reference

9 August 2017

119-129

1 reference

Regulation of the expression of epidermal keratinocyte proliferation and differentiation by vitamin A analogs

9 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.119

Safety issues in isotretinoin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.119

Risk management strategies in the Physicians' Desk Reference product labels for pregnancy category X drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.119

Uses and complications of isotretinoin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.119

Analysis of common side effects of isotretinoin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.119

Delayed wound healing and keloid formation following argon laser treatment or dermabrasion during isotretinoin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.119

Acne fulminans and 13-cis-retinoic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.119

The treatment of acne fulminans: a review of 25 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.119

Acne fulminans and erythema nodosum during isotretinoin therapy responding to dapsone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.119

Isotretinoin-induced nail fragility and onycholysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.119

Herpetic whitlow during isotretinoin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.119

Severe acute myopathy induced by isotretinoin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.119

Isotretinoin effects on bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.119

Premature epiphyseal closure in a child receiving oral 13-cis-retinoic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.119

Retinoid-induced epiphyseal plate closure in guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.119

Prospective study of depressive symptoms and quality of life in acne vulgaris patients treated with isotretinoin compared to antibiotic and topical therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.119

The association between depression and isotretinoin use in acne

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.119

Depression and suicide in patients treated with isotretinoin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.119

Isotretinoin use and risk of depression, psychotic symptoms, suicide, and attempted suicide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.119

The psychological and emotional impact of acne and the effect of treatment with isotretinoin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.119

Reduced anxiety and depression in cystic acne patients after successful treatment with oral isotretinoin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.119

Three independent lines of evidence suggest retinoids as causal to schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.119

Neurobehavioral teratology of isotretinoin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.119

21 January 2018

Drug-related headache.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.119

Effects of oral isotretinoin on human auditory brainstem response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.119

Pseudotumor cerebri caused by a synthetic vitamin A preparation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.119

Isotretinoin-Induced Inflammatory Bowel Disease in an Adolescent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.119

Rheumatological symptoms due to retinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.119

Post-isotretinoin vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.119

Delayed onset of vasculitis following isotretinoin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.119

Severe vasculitis during isotretinoin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.119

Renal impairment induced by isotretinoin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.119

Nephrotic syndrome associated with isotretinoin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.119

Analysis of laboratory data in acne patients treated with isotretinoin: is there really a need to perform routine laboratory tests?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.119

A proposed set of new guidelines for routine blood tests during isotretinoin therapy for acne vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.119

Drug-Induced lipid changes: a review of the unintended effects of some commonly used drugs on serum lipid levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.119

Dyslipidemia and a reversible decrease in insulin sensitivity induced by therapy with 13-cis-retinoic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.119

Treatment of severe acne with isotretinoin in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.2.119

21 January 2018

Identifiers

DOI

10.1517/14740338.3.2.119

1 reference

9 August 2017

1 reference